IGSF11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28732507	1.00	1/20
SCHEMBL16896199	0.59	1/20
SCHEMBL16896193	0.56	1/20
SCHEMBL29548800	0.56	1/20
SCHEMBL16896196	0.55	1/20
SCHEMBL16906386	0.55	1/20
SCHEMBL16896047	0.53	1/20
SCHEMBL16896225	0.53	1/20
SCHEMBL16896088	0.53	1/20
SCHEMBL16896202	0.53	1/20
SCHEMBL16896224	0.53	1/20
SCHEMBL13603660	0.52	1/20
SCHEMBL13282918	0.51	1/20
SCHEMBL19079683	0.51	1/20
SCHEMBL13283028	0.50	1/20
SCHEMBL10736120	0.48	1/20
SCHEMBL13283024	0.48	1/20
SCHEMBL7842505	0.47	1/20
SCHEMBL7844440	0.47	1/20
SCHEMBL12713406	0.47	1/20

Clinical trials — most relevant to IGSF11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency	PHASE4	COMPLETED
co Ihibtory Receptor in Preeclampsia	PHASE4	UNKNOWN
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency	PHASE3	RECRUITING
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease	PHASE3	RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma	PHASE2	UNKNOWN
Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma	PHASE2	UNKNOWN
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus	PHASE2	COMPLETED
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE2	COMPLETED
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies	PHASE1/PHASE2	UNKNOWN
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma	PHASE2	UNKNOWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme	PHASE1	COMPLETED
Post IVIG Medication in Children With Immune Thrombocytopenia	PHASE1	UNKNOWN
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer	PHASE1	SUSPENDED
Phase I Study of MOv18 IgE	PHASE1	COMPLETED
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level	nan	COMPLETED
Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents	nan	COMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer	nan	COMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IGSF11 binder may also engage these)

Protein	Name	Similarity
Q5U2P2	—	1.000	Q5U2P2 →
P0C673	—	1.000	P0C673 →
Q08DK1	—	1.000	Q08DK1 →
Q58EG3	—	0.992	Q58EG3 →
Q90Y50	—	0.992	Q90Y50 →
Q5VJ70	—	0.992	Q5VJ70 →
Q6AYD4	—	0.992	Q6AYD4 →
Q8WMV3	—	0.989	Q8WMV3 →
Q5FWR8	—	0.988	Q5FWR8 →
P97792	—	0.987	P97792 →
Q7TSN7	—	0.986	Q7TSN7 →
Q99795	—	0.986	Q99795 →
Q925F2	—	0.985	Q925F2 →
P78310	—	0.985	P78310 →
Q9JKA5	—	0.984	Q9JKA5 →
Q9R066	—	0.984	Q9R066 →
Q6X936	—	0.984	Q6X936 →
A0A8M2B818	—	0.983	A0A8M2B818 →
Q5R764	—	0.982	Q5R764 →
Q91664	—	0.982	Q91664 →
Q86XK7	—	0.981	Q86XK7 →
Q96J84	—	0.980	Q96J84 →
Q80W68	—	0.980	Q80W68 →
D3YX43	—	0.979	D3YX43 →
Q9W7R4	—	0.979	Q9W7R4 →
Q96AP7	—	0.979	Q96AP7 →
Q9D2J4	—	0.979	Q9D2J4 →
Q6DJ83	—	0.979	Q6DJ83 →
Q99P91	—	0.978	Q99P91 →
D3ZTV3	—	0.978	D3ZTV3 →